Guilin Sanjin Pharmaceutical Co Ltd (002275) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, manufacturing, and sale of traditional Chinese medicines in China and internationally.
Total Cash From Operating Activities Chart for Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co Ltd (002275) operating cash flow for FY2025 was CNY 708.1M, a 20.4% change from FY2024. Guilin Sanjin Pharmaceutical Co Ltd's operating cash flow grew from CNY 217.7M in 2006 to CNY 708.1M in 2025 (225.3% over 19 years). Operating cash flow compound annual growth rate: 5-year CAGR of 3.4%, 10-year CAGR of 5.9%.
Total Cash From Operating Activities (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥7.27B
- Implied Share Price
- ¥12.37
- Enterprise Value
- ¥6.20B
- Revenue (TTM)
- ¥2.02B
- EBITDA
- ¥646.32M
- Profit Margin
- 20.19%
- Trailing P/E
- 17.93
- Forward P/E
- 19.96
- Price/Book (MRQ)
- 2.23
- Price/Sales (TTM)
- 3.61
- EV/EBITDA
- 9.22
- EV/Revenue
- 3.07
- Dividend Yield
- 4.02%
- Book Value
- ¥5.51
- Free Cash Flow (FY2025)
- ¥621.18M
- Free Cash Flow Yield
- 8.55%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.